131 results
Page 3 of 7
8-K
EX-99.2
vtam7xi95 df0mn2e
12 Jun 20
Entry into a Material Definitive Agreement
7:04am
8-K
EX-99.3
626b skgqs69e
12 Jun 20
Entry into a Material Definitive Agreement
7:04am
S-3ASR
EX-1.2
1em o508qjo
30 Apr 20
Automatic shelf registration
4:19pm
8-K
EX-99.1
2qm1r
30 Apr 20
Agios Reports First Quarter 2020 Financial Results and Provides Update on Business Operations andCOVID-19 Response
7:19am
8-K
EX-99.1
krvddm
13 Jan 20
Regulation FD Disclosure
4:32pm
8-K
EX-99.1
mw92o
9 Dec 19
Agios EstablishesProof-of-Concept for Mitapivat inNon-transfusion-dependent Thalassemia Based on Preliminary Phase 2 Results
4:02pm
8-K
EX-99.3
4pz 3nybaxjvdja
9 Dec 19
Agios EstablishesProof-of-Concept for Mitapivat inNon-transfusion-dependent Thalassemia Based on Preliminary Phase 2 Results
4:02pm
8-K
EX-99.2
7z2 2z15uz79tn
9 Dec 19
Agios EstablishesProof-of-Concept for Mitapivat inNon-transfusion-dependent Thalassemia Based on Preliminary Phase 2 Results
4:02pm
8-K
EX-99.1
gags9 2rfrro
22 Nov 19
Other Events
5:01pm
424B5
8h75a8x93z3n n4w
8 Nov 19
Prospectus supplement for primary offering
5:03pm
8-K
EX-1.1
l6urxhd3eu3g
8 Nov 19
Agios Announces Pricing of $256 Million Public Offering of Common Stock
4:57pm
424B5
heyu9wih6
6 Nov 19
Prospectus supplement for primary offering
4:07pm
8-K
EX-99.1
8xjy9
28 Oct 19
Agios Presents Data from Single Agent Dose-Escalation Arm of Phase 1 Study ofAG-270, a MAT2A Inhibitor, in Patients withMTAP-Deleted Tumors
7:20am
8-K
EX-99.1
ctthdwz6e453w
30 Sep 19
Other Events
11:13am
8-K
EX-99.1
e3g18lzp21 lj
4 Sep 19
Other Events
5:05pm